Navigation Links
RLIP76 contributes to pancreatic cancer cell resistance to chemotherapy and radiation
Date:6/19/2012

LAKE TAHOE, Nev. Researchers at the City of Hope Comprehensive Cancer Center have not only identified a protein that allows pancreatic cancer cells to resist therapy but also developed a way to block it, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

"Cancer of the pancreas is notoriously difficult to treat because it usually presents at late stages due to minimal or nonspecific symptoms in the early stages. Thus, surgical treatment is either not possible or fails to cure most patients, resulting in a dismal prognosis 90 percent of patients are likely to die within a year," said Sanjay Awasthi, M.D., professor of medical oncology and therapeutics research, and diabetes, endocrinology and metabolism at City of Hope in Duarte, Calif.

One of the reasons that pancreatic cancer is so difficult to treat is that the tumor cells are largely resistant to the cell death caused by radiation and chemotherapy. Awasthi and colleagues have previously shown that the protein RLIP76 plays a key role in defending cells from other types of cancers from death caused by exposure to chemotherapy or radiation.

"RLIP76 works like an exhaust system," said Awasthi. "It pumps out the toxic chemicals that accumulate in the cancer cell as a result of chemo- or radiotherapy before they can cause cell death."

Now, Awasthi and colleagues have found that there is more RLIP76 in human pancreatic cancer cells than there is in normal human pancreatic cells. Depleting levels of RLIP76 killed human pancreatic cancer cells in culture and shrank established human pancreatic tumors in mice. Moreover, blocking RLIP76 or depleting levels of the protein dramatically enhanced the ability of radiation and the chemotherapeutic agent doxorubicin to destroy human pancreatic cells in culture.

"Pancreatic cancer patients are a special case of the particularly unlucky, and in many ways the most miserable. The drug and radiation resistance of this cancer is legendary," Awasthi said.

"Because we have defined RLIP76 as an essential drug- and radiation-resistance mediating protein, and because blockade of RLIP76 caused regression of less therapy-resistant cancers (lung, colon, breast), as well as equally resistant cancers (kidney, prostate, resistant neuroblastoma), we undertook the present studies to determine whether this treatment could be effective in pancreatic cancer.

"Fortunately, our data show that the seemingly unconquerable pancreatic cancer has an Achilles heel; its toxin exhaust system," he explained. "Moreover, plugging this exhaust caused pancreatic cancer cell death, leaving normal cells relatively unfazed. We hope to translate these studies into clinical trials in the near future."

According to Awasthi, they saw an added benefit to depleting levels of RLIP76 in the mice with established tumors: a decrease in blood sugar, cholesterol and triglycerides. "These findings indicate that it might be possible to develop a single class of medications that have potent antidiabetic and anticancer effects," he said.

Awasthi is the founder of Terapio, which makes the recombinant RLIP76 protein for treatment of radiation poisoning. However, Terapio does not work on the RLIP76-blockading technology that is the crux of the anticancer treatment strategy.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Stress contributes to cognitive declines in women with breast cancer, researcher says
2. Social-class discrimination contributes to poorer health
3. Short Walks May Ease Fatigue in Pancreatic Cancer Patients
4. Mutant Kras drives pancreatic cancer maintenance via metabolic pathways
5. Early biomarker for pancreatic cancer identified
6. Researchers present new findings for novel pancreatic cancer vaccine
7. Studies See Advances in Detecting, Treating Pancreatic Cancer
8. Nerve growth factors elevated in pancreatic cancer model
9. Sun exposure and sun-sensitive skin type decreased risk for pancreatic cancer
10. Inhibiting Hedgehog signaling pathway may improve pancreatic cancer treatment
11. Study Suggests Vaccine May Help Kids With Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... To better understand the ... research award to examine gender differences in lung cancer. Today, the Lung Association announced ... Lung Cancer in Women Award, funded by the American Lung Association’s LUNG FORCE initiative, ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... Roberta Jordan. , Roberta Jordan is a Certified Nurse Midwife who was ... State University and then went on to complete her masters degree from the ...
(Date:5/24/2016)... ... ... Jericho Project has named LaToya Williams-Belfort to the position of Chief Development and Communications ... the nationally-acclaimed nonprofit, working closely with CEO Tori Lyon and the Board of Directors ... , “LaToya Williams-Belfort is joining Jericho at an exciting time of growth and ...
(Date:5/24/2016)... ... May 24, 2016 , ... Altura ... today announced a strategic partnership with Five9 (Nasdaq: FIVN), a leading provider ... of Avaya’s largest Platinum Business Partners, is a leading provider of communication-enabled ...
(Date:5/24/2016)... ... 24, 2016 , ... Local engineering firm, Timmons Group, announced ... located in Woodbridge, VA. The project includes a brand new operating room ... The new 2 story building houses the Central Sterile department, Sterile prep area ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... 2016 Clarifying Vision - Prospects ... and Vision Care What can be expected ... to grow at the fastest rates? This visiongain ... data, trends, opportunities and prospects. ,Our ... the most lucrative areas in the industry and the ...
(Date:5/23/2016)... 2016 Gamida Cell, a leader ... cancer and orphan genetic diseases, announced today it has ... from the Israel Innovation Authority (formerly the Office of ... and Industry. The mission of the Israel Innovation Authority ... including science and technology, while stimulating economic growth. ...
Breaking Medicine Technology: